Dr. Davis is currently the Chief Operating Officer of Biosion Inc., a clinical stage, antibody-based therapeutic biotechnology company with sites in Nanjing, China and Newark, DE. Hugh has a 35+ year career in the discovery and development of novel therapeutics at major pharmaceutical and biotechnology companies, including 20 years at Johnson & Johnson. Additionally, Hugh was the CBO of Frontage Laboratories, where he led Business Development and Sales and Marketing.
Hugh was the VP and Head of the Biologics Development Sciences department in Janssen Biotherapeutics (JBIO), leading a group of up to 200+ scientists in the biophysical characterization of discovery assets. In addition, over the last 5-6 years in JBIO at J&J, Hugh was also the China Biologics Leader. Together with his team, Dr. Davis was instrumental in the development and approval of many biologic therapies at J&J . Following his tenure at J&J, Dr. Davis took the role of Chief Business Officer at Frontage Laboratories, leading the company to a very successful IPO, on the Hong Kong Exchange (HKSE: 1521) . Currently, Dr. Davis is the COO of Biosion, Inc. and President of Biosion USA, Inc. where he has built a team focused on the Preclinical, Regulatory, Quality, Clinical and Business Development efforts for antibody-based portfolio assets moving toward IND submission and Clinical Development.
Dr. Davis holds a Ph.D. degree in Biochemistry from Villanova University and completed post-Doctoral training at Centocor, Inc. where he patented the characterization of the tumor biomarker for ovarian cancer, CA125.